Quick Facts
Plain-English Summary
VIP is an endogenous signaling molecule with widespread physiological roles across the cardiovascular, pulmonary, gastrointestinal, and immune systems. It binds VPAC1 and VPAC2 receptors (coupled to adenylate cyclase/cAMP) expressed ubiquitously in these tissues. Its potent vasodilatory and bronchodilatory properties were recognized early; its immunomodulatory functions have been increasingly characterized over the past 20 years.
The immunomodulatory profile is scientifically credible: VIP downregulates TNF-α, IL-6, IL-12 production in activated macrophages and dendritic cells; promotes IL-10 and TGF-β; and induces expansion of regulatory T cells (Tregs). In animal models of rheumatoid arthritis, colitis, multiple sclerosis, and lung inflammation, VIP administration reduces disease severity. These findings have been replicated across independent laboratories.
The major translational barrier is pharmacokinetics. Native VIP has a plasma half-life of under 2 minutes — it is degraded almost instantly by plasma peptidases. This makes systemic administration impractical as a therapy without either continuous infusion, analogue development, or novel delivery systems. Intranasal VIP has been investigated, but absorption and CNS penetrance via this route are highly variable.
A specific clinical narrative around VIP nasal spray has developed in the 'biotoxin illness' or CIRS (Chronic Inflammatory Response Syndrome) community, associated with Dr. Ritchie Shoemaker's protocol. This use is not supported by peer-reviewed RCTs and the underlying CIRS diagnostic framework is not recognized as valid by mainstream immunology or pulmonology societies. Users should carefully distinguish the legitimate anti-inflammatory science of VIP from the specific CIRS protocol claims.
VIP has real, peer-reviewed anti-inflammatory biology. The therapeutic application of this biology — particularly via compounded nasal spray for CIRS or mold illness — is not supported by controlled clinical trial data. The CIRS diagnostic framework itself is contested. Patients pursuing VIP nasal spray through this protocol should understand they are acting on a clinical framework that lacks mainstream medical validation, not just on a research compound in the usual sense.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rat — collagen-induced arthritis | VIP (1 nmol/kg SC daily) significantly reduced paw inflammation, joint destruction, and inflammatory cytokines vs controls. Delgado et al. 2002 ↗ | Preclinical |
| Mouse — experimental autoimmune encephalomyelitis (MS model) | VIP reduced CNS inflammation, demyelination, and T cell infiltration; improved motor scores vs controls. Treg induction confirmed. | Preclinical |
| Rat — pulmonary hypertension | Inhaled VIP reduced pulmonary artery pressure and vascular remodeling in monocrotaline-induced PAH; effects comparable to standard-of-care agents in this model. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Pulmonary arterial hypertension (Inhaled VIP) | PAH patients (n=8) open-label | — | Limited |
| CIRS nasal spray protocol | CIRS patients | — | No Data |
| VIPoma diagnosis | Adults | — | Approved |
VIP has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Short-term IV VIP in research settings appears safe. Nasal spray at doses used in CIRS protocols (50mcg per nostril) appears to be physically well tolerated based on patient self-reports, with nasal irritation the main complaint. No serious adverse events reported in the limited literature.
Long-term safety of chronic intranasal VIP is unknown. No human toxicology package exists. The primary theoretical concern is that VPAC1 and VPAC2 are expressed on many cell types including some tumors — chronic VIP receptor stimulation in users with undetected malignancy is an unanswered question.
- Nasal irritation or burning
- Headache (rare)
- Transient hypotension (with higher doses/IV)
- Exacerbation of existing hypotension
- Active or suspected malignancy (VPAC receptor expressed on many tumor types)
- Existing hypotension or cardiovascular instability
- Pregnancy or breastfeeding
- Children and adolescents (no data)
VIP is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of VIP for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
I have a genuine CIRS diagnosis and VIP nasal spray was the last step in the protocol. It did help me. But I also acknowledge I went through 10 other interventions first and it's impossible to know what worked. I'm not going to tell anyone this is proven — it isn't.
The basic VIP immunology is solid and interesting. VPAC signaling, Treg induction, cytokine suppression — all real. The CIRS specific application is a completely different question and the protocol built around it has not been validated in RCTs.
The VIP-CIRS connection is built on Shoemaker's work which has not been replicated by independent researchers using blinded methodology. The biomarker panel he uses (C4a, TGF-b1, VEGF) doesn't have established normal ranges in most labs. Compelling anecdotes, weak evidence.
The PAH inhaled VIP data from 2003 was promising but never led anywhere — pharma couldn't figure out a stable inhaled formulation with good pharmacokinetics. The science was compelling. Execution was the problem.